268 related articles for article (PubMed ID: 35990677)
1. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
Front Immunol; 2022; 13():871756. PubMed ID: 35990677
[TBL] [Abstract][Full Text] [Related]
2. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
Front Immunol; 2022; 13():894110. PubMed ID: 35967450
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Value of
Ye T; Zhang JY; Liu XY; Zhou YH; Yuan SY; Yang MM; Xie WZ; Gao C; Chen YX; Huang ML; Ye CZ; Chen J
Front Immunol; 2021; 12():785526. PubMed ID: 35069558
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
[TBL] [Abstract][Full Text] [Related]
7. Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
Zhang J; Tang S; Zhang C; Li M; Zheng Y; Hu X; Huang M; Cheng X
Front Oncol; 2021; 11():742833. PubMed ID: 35087742
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
10. Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
Nakamura Y; Namikawa K; Kiniwa Y; Kato H; Yamasaki O; Yoshikawa S; Maekawa T; Matsushita S; Takenouchi T; Inozume T; Nakai Y; Fukushima S; Saito S; Otsuka A; Fujimoto N; Isei T; Baba N; Matsuya T; Tanaka R; Kaneko T; Onishi M; Kuwatsuka Y; Nagase K; Onuma T; Nomura M; Umeda Y; Yamazaki N
Eur J Cancer; 2022 Nov; 176():78-87. PubMed ID: 36194906
[TBL] [Abstract][Full Text] [Related]
11. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
[TBL] [Abstract][Full Text] [Related]
12. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
[TBL] [Abstract][Full Text] [Related]
13. The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.
Chen J; Tang Y; Liu H; Sun G; Liu H; Zhao J; Wang Z; Zhang Y; Lou F; Cao S; Qin J; Wang H; Liao B; Zeng H
Cancer Med; 2023 Dec; 12(24):22370-22380. PubMed ID: 37986697
[TBL] [Abstract][Full Text] [Related]
14. DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study.
Xiao Z; Sun L; Zheng Y; Chen H; Zheng X; Luo J; Gu C; Lin R; Huang M; Bai Y; Chen ZS; Kinslow CJ; Loh J; Lin L
Transl Lung Cancer Res; 2022 Dec; 11(12):2539-2566. PubMed ID: 36636408
[TBL] [Abstract][Full Text] [Related]
15. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Campbell KM; Amouzgar M; Pfeiffer SM; Howes TR; Medina E; Travers M; Steiner G; Weber JS; Wolchok JD; Larkin J; Hodi FS; Boffo S; Salvador L; Tenney D; Tang T; Thompson MA; Spencer CN; Wells DK; Ribas A
Cancer Cell; 2023 Apr; 41(4):791-806.e4. PubMed ID: 37037616
[TBL] [Abstract][Full Text] [Related]
16. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
17. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.
Vlachostergios PJ
Am J Transl Res; 2021; 13(11):12386-12394. PubMed ID: 34956460
[TBL] [Abstract][Full Text] [Related]
18. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA; Fekete JT; Győrffy B
Acta Pharmacol Sin; 2023 Sep; 44(9):1879-1889. PubMed ID: 37055532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
